Studying stool test for digestive disease diagnosis
Part of Digestive system clinical trials.
This trial tests a new stool test to measure calprotectin levels, which could help doctors tell the difference between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). If you have symptoms like stomach pain, diarrhea, or weight loss and are about to have a colonoscopy, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 22 years or older.
- You have symptoms like stomach pain, diarrhea, changes in appetite, weight loss, or low blood counts that might be due to IBD or IBS.
- You can give a stool sample within 72–24 hours before your scheduled colonoscopy or 3–30 days after it.
- You have no active bowel cancer, active gut infection, or certain stomach conditions that could interfere.
- You have not taken NSAIDs (like ibuprofen or aspirin) on 7 or more days in the past two weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests non-invasive tools to find active inflammation in people with Crohn's disease or ulcerative colitis. You may need to give extra stool samples before your colonoscopy and calprotectin test.
This study collects stool samples and health information to help develop a new test that may tell the difference between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). If you have not been diagnosed with a chronic gut disorder, you may be able to join.
This study checks if a stool test (fecal calprotectin) can help doctors tell apart different causes of long-term stomach and bowel symptoms in children. It might help avoid unnecessary invasive tests like endoscopy.
This study tests a new way to monitor ulcerative colitis using stool tests and colonoscopy to detect early signs of cancer. It may help doctors manage long-term ulcerative colitis more safely.
This study checks whether adding an extra, cross-body “transmural” evaluation (looking at inflammation throughout the bowel) improves care for adults with Crohn’s who are starting or receiving biologic (biotherapy) treatment. It uses close follow-up with stool calprotectin (a marker of gut inflammation) to see if this approach helps control inflammation.
This study follows people with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who may be taking immunosuppressants (medicines that calm the immune system). Researchers will track how the disease progresses and look at factors like gut bacteria to find ways to predict complications.
Hear when a new Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.